期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 60, 期 1, 页码 666-668出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01964-15
关键词
-
资金
- Merck & Co., Inc., Kenilworth, NJ, USA
The in vitro activities of ceftolozane-tazobactam, meropenem, and metronidazole were determined against anaerobic organisms isolated from patients with complicated intraabdominal infections (cIAI) in global phase III studies. Ceftolozane-tazobactam activity was highly variable among different species of the Bacteroides fragilis group, with MIC90 values ranging from 2 to 64 mu g/ml. More-potent in vitro activity was observed against selected Gram-positive anaerobic organisms; however, small numbers of isolates were available, and, therefore, the clinical significance of these results is unknown. Variable activity of ceftolozanetazobactam against anaerobic organisms necessitates use in combination with metronidazole for the treatment of cIAI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据